UroGen Pharma Ltd. (NASDAQ:URGN) Receives $38.20 Average PT from Brokerages
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 […]
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 […]
